Mehran Risk Score for CIN

Clinical Overview & History

The Mehran Risk Score, published by Dr. Roxana Mehran and colleagues in 2004 in the Journal of the American College of Cardiology, is a clinical prediction model designed to estimate the risk of contrast-induced nephropathy (CIN) and the subsequent risk of post-procedural dialysis. This score is specifically validated for patients undergoing percutaneous coronary intervention (PCI) or coronary angiography.

Contrast-induced nephropathy—also referred to as contrast-associated acute kidney injury (CA-AKI)—represents a significant complication in cardiac catheterization laboratories. It is defined as a decline in renal function, marked by an increase in serum creatinine of $\geq 25%$ or $\geq 0.5\text{ mg/dL}$ from baseline, occurring within 48 to 72 hours after the intravascular administration of iodinated contrast media. The development of CIN is strongly linked to prolonged hospitalization, increased healthcare costs, and a significant rise in both short-term and long-term mortality.

Pathophysiology and Scoring Criteria

The pathophysiological mechanisms of CIN involve direct cytotoxic damage to the renal tubular epithelial cells by the iodinated contrast agents, coupled with vasoconstriction of the renal vasculature, which induces medullary ischemia. These events are compounded by oxidative stress and tubular obstruction.

The Mehran Risk Score quantifies a patient's vulnerability to these insults by compiling points across eight clinical, hemodynamic, and procedural risk variables:

1. Hypotension (5 points): Defined as systolic blood pressure $< 80\text{ mmHg}$ for at least 1 hour requiring inotropic support within 24 hours of the procedure.
2. Intra-Aortic Balloon Pump (IABP) Support (5 points): Indicates severe hemodynamic instability or cardiogenic shock, requiring mechanical circulatory assistance.
3. Congestive Heart Failure (CHF) (5 points): Class III/IV heart failure according to the New York Heart Association (NYHA) classification or a history of acute pulmonary edema.
4. Age $> 75$ Years (4 points): Age-related decline in nephron mass and renal reserve increases vulnerability to toxic insults.
5. Anemia (3 points): Hematocrit $< 39%$ for males and $< 36%$ for females, reducing renal medullary oxygen delivery.
6. Diabetes Mellitus (3 points): Promotes microvascular disease and renal hypoxia, predisposing the kidneys to contrast toxicity.
7. Contrast Volume (1 point per 100 mL): Contrast toxicity is dose-dependent; 1 point is added for every $100\text{ mL}$ of contrast media administered.
8. Estimated Glomerular Filtration Rate (eGFR): Pre-existing renal impairment is the strongest predictor. Points are assigned based on baseline eGFR:
   • eGFR $> 60\text{ mL/min/1.73m}^2$: 0 points
   • eGFR $40 - 60\text{ mL/min/1.73m}^2$: 2 points
   • eGFR $20 - 40\text{ mL/min/1.73m}^2$: 4 points
   • eGFR $< 20\text{ mL/min/1.73m}^2$: 6 points

Formula & Scoring Interpretation

The total Mehran Score is calculated as the sum of the points:

The calculated total score corresponds to four distinct risk tiers:

• Score \leq 5 (Low Risk): Risk of CIN $\approx 7.5%$; risk of requiring post-procedural dialysis $\approx 0.04%$.
• Score 6–10 (Moderate Risk): Risk of CIN $\approx 14.0%$; risk of requiring post-procedural dialysis $\approx 0.12%$.
• Score 11–15 (High Risk): Risk of CIN $\approx 26.1%$; risk of requiring post-procedural dialysis $\approx 1.09%$.
• Score \geq 16 (Very High Risk): Risk of CIN $\approx 57.3%$; risk of requiring post-procedural dialysis $\approx 12.6%$.

Step-by-Step Clinical Scenario

Consider a clinical case: A 78-year-old female patient with a history of NYHA Class III congestive heart failure and diabetes mellitus undergoes coronary angiography and PCI for an acute coronary syndrome. Her baseline hematocrit is 32% (anemia). Her eGFR is calculated as $35\text{ mL/min/1.73m}^2$. During the procedure, she remains hemodynamically stable without needing an IABP, and a total of $200\text{ mL}$ of contrast media is used.

Let's calculate the Mehran Score for this patient:

• Hypotension: No (0 points)
• IABP: No (0 points)
• Congestive Heart Failure: Yes (5 points)
• Age $> 75$ Years: Yes (4 points)
• Anemia: Yes (3 points)
• Diabetes: Yes (3 points)
• Contrast Volume: $200\text{ mL}$ ($2 \times 100\text{ mL} \to$ 2 points)
• eGFR $20-40\text{ mL/min/1.73m}^2$: Yes (4 points)

$\text{Total Score} = 0 + 0 + 5 + 4 + 3 + 3 + 2 + 4 = 21$

A score of 21 places this patient in the Very High Risk category (score $\geq 16$), representing a 57.3% risk of developing contrast-induced nephropathy and a 12.6% risk of requiring dialysis.

Clinical Utility and Mitigation Strategies

The clinical utility of the Mehran Risk Score lies in its ability to alert the cardiac care team to implement kidney-sparing strategies before, during, and after the coronary procedure. For high or very high-risk patients, the following mitigation protocols are strongly recommended:

• Intravenous Hydration: Adequate volume expansion with isotonic saline ($1.0 - 1.5\text{ mL/kg/h}$) or sodium bicarbonate before and after contrast exposure is the cornerstone of prevention.
• Minimize Contrast Volume: Proceduralists should aim for a contrast-to-eGFR ratio $< 3.0$ to minimize renal toxicity.
• Choice of Contrast Agent: Utilizing iso-osmolar (e.g., iodixanol) or low-osmolar contrast media.
• Withhold Nephrotoxins: Suspending nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, and metformin prior to the procedure.
• Staged Procedures: Delaying non-urgent interventions to allow renal recovery.

⚠️ Medical Disclaimer: This calculator is for educational and reference purposes only. It is not intended to diagnose, treat, or cure any disease, and should not be used as a substitute for professional clinical judgment.